AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03836599
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Combination Product: BGFCombination Product: GFF
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT03836677
- Locations
- π³π±
Research Site, Zutphen, Netherlands
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Phase 3
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 724
- Registration Number
- NCT03833154
- Locations
- π¬π§
Research Site, Manchester, United Kingdom
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Completed
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 170
- Registration Number
- NCT03833141
- Locations
- π¨π¦
Research Site, Saskatoon, Saskatchewan, Canada
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Phase 3
Completed
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Biological: DurvalumabRadiation: external beam radiation therapy (EBRT) + brachytherapy
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 770
- Registration Number
- NCT03830866
- Locations
- π¨π³
Research Site, Taoyuan City, Taiwan
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- πΉπ
Research Site, Hat Yai, Thailand
A Disease Registry of Patients With Mantle Cell Lymphoma
Completed
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 229
- Registration Number
- NCT03816683
- Locations
- πΊπΈ
Research Site, Milwaukee, Wisconsin, United States
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Phase 3
Recruiting
- Conditions
- Hyperkalaemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose LevelDrug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)Drug: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT03813407
- Locations
- π¬π§
Research Site, Nottingham, United Kingdom
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT03804645
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
Assessment of Asthma Control Level in Primary Care Setting in Malaysia
Completed
- Conditions
- Asthma Control Level
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1011
- Registration Number
- NCT03804632
- Locations
- π²πΎ
Research Site, Kuala Terengganu, Terengganu, Malaysia
Β© Copyright 2025. All Rights Reserved by MedPath